Why the study?
Studies of cardiac function in adolescent and young adult survivors have typically been performed at least a decade after anthracycline exposure, leaving little knowledge of short-term changes in cardiac function in this age group.
Do high-dose anthracyclines cause short-term declines in cardiac function in adolescent and young adult osteosarcoma patients?
Do high-dose anthracyclines cause short-term declines in cardiac function in adolescent and young adult osteosarcoma patients?
High-dose anthracycline therapy in osteosarcoma patients is associated with significant short-term declines in systolic and diastolic cardiac function within 2 years of treatment.
Answers are grounded in this paper and cite their sources.
Early LVEF declines warrant prompt surveillance in AYA anthracycline recipients; leaves open optimal protocols and long-term risk.
Studies of cardiac function in adolescent and young adult survivors have been performed at least a decade after anthracycline exposure, with little knowledge of short-term changes in cardiac function in this age group. To this end, we evaluated cardiac function within a 2-year period among 18 patients who received high-dose anthracyclines for osteosarcoma treatment. At 2 years, there was a significant decline in left ventricular ejection fraction (p = 0.005), with 8 of 18 patients having a >10% reduction. There was a significant change in E-wave velocity (p = 0.04). To our knowledge, this is the first study assessing short-term change in systolic and diastolic function in osteosarcoma patients receiving anthracyclines.
No takes yet. Share an insight, caveat, or question.
Gilchrist et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: